Oregon Drug Use Review Board

Office of Medical Assistance Programs
State of Oregon
September 7, 2001
Meeting Minutes

The meeting was held at the Department of Human Services Building, 500 Summer Street NE, Salem.

BOARD MEMBERS present: Rick Asai, D.M.D., Gregory Johnson, M.D., Dean Haxby, Pharm. D., Cliff Singer, M.D., Patrick Bowman, R.Ph., Robert Mendelson, M.D., Raymond Lee, D.O., Christina Heinrich, Pharm. D., Sharon Leigh, Pharm. D., Robert Ingle, M.D. and Jerry D. Fairbanks, R.Ph. attended via conference phone. Jim Winde, M.D. was absent.

OMAP STAFF and CONTRACTORS present: Jesse Anderson (OMAP), Jim Edge (OMAP), Kurt Furst (OMAP), Tom Turek, (OMAP), Mariellen Rich (FHSC), Rose-Ellen Hope (FHSC), Kathy Ketchum (OSU) and Ann Hamer (OSU).

GUESTS present: Paul Nielsen (Pharmacia), Karen Nishihara (Pharmacia), and Joe Fuller (AstraZeneca).

I. CALL TO ORDER

a. Roll call was taken and introductions were made. A quorum was present. The meeting was called to order by Ch. Asai at 1:40 PM.

b. The minutes were approved. The agenda packet was approved with two changes and one addition. Items IIId and IVa were moved to the front of the agenda and pages 30a-b were distributed at the meeting.

c. The Board heard a letter written by PhRMA Counsel Jim Gardner to Jesse Anderson read into the record by Paul Nielson (attached).

II. OLD BUSINESS

a. Gabapentin Use Criteria

The Board reviewed the report.
Action: The Board recommended the College review the other drugs in this class and develop use criteria for all and bring this back to the November meeting.

b. Sedative / Hypnotic Use Criteria

The Board reviewed the criteria. There was discussion about potential shifts in drug choice this could cause as well as potential actions that could be taken short of quantity restrictions.

Action: Dr. Singer to assist the College in development of a treatment algorithm for educational purposes to accompanying quantity restriction and bring this back to the November meeting.
Action: Add ProDUR criteria for age contraindication (>65) for flurazepam and quazepam.

c. General Discussion on ProDUR Criteria
The Board reviewed the report.
Action: Ms. Hope to collect data on the potential effects of a routine policy of high dose denials at 150% above the maximum recommended dose by testing it in the RetroDUR program.

d. Conflict of Interest Declaration
The Board reviewed the declaration.
Action: Mr. Anderson to confirm with OMAP Attorney General the viability of this policy.
Action: Pending AG approval the Board recommended that the Board, Board staff and DUR Council begin a policy of annual declaration of conflict. Those wishing to testify would also be asked to declare conflict at the time of testimony.

III. REPORTS

a. OMAP Drug Utilization PMPM Report
The Board reviewed the report.

b. New Drug Report
The Board reviewed the report.

c. ProDUR Alert Analysis by Class
The Board reviewed the report.

d. Review of Antiulcer Therapy and PA Criteria Recommendation
The Board reviewed the report.
Action: The Board recommended removal of prior authorization for generic H2-Antagonists and accepted recommended changes for brand products (attached).
Action: The Board recommended removal of prior authorization for generic PPIs (when available) and accepted recommended changes to the criteria with some modifications (attached).
Action: The Board recommended, if no generic PPI is available at the time of implementation, continuing the current availability of 8 weeks of PPI therapy before prior authorization.

e. ProDUR Report & FHSC Clinical Alerts
The Board reviewed the report.
Action: Delete drug-drug interaction criteria for Ziprasidone-Olanzepine.

f. ProDUR Criteria Review
The Board reviewed ProDUR Criteria for the Anti-Ulcer Drugs and Selected New Drugs.
Action: The Board adopted the criteria in the attached grids.

g. RetroDUR Report
The Board reviewed the report.

h. Education Report
Dr. Haxby reported the DUR Board Newsletter distribution options, reviewed the proposed upgrade to the web-site and updated the Board on academic detailing pilots.

IV. NEW BUSINESS

a. Legislative Update
Mr. Anderson reported on legislative items affecting drug utilization and reimbursement. The Health Resources Commission is tasked with development of a formulary for OMAP fee-for-service. There is planned to be coordination between the HRC and the DUR Board to avoid conflicting policies. The OMAP budget legislation mandated a pharmacy dispensing fee reduction (10/01), a voluntary co-payment for drugs (requires a CMS waiver) and development of a state MAC (01/02). The governor directed that OMAP implement a policy of denying claims without provider numbers, antidepressant case management, a pharmacy lock-in program (needs a CMS waiver) and a disease-state management program (7/02).

b. Meeting Schedule for 2001-2002.
Action: Meeting time is 1:30-4:30 PM and the dates are:

November 14, 2001 - DHS 457
February 5, 2002 - DHS 137AB
May 7, 2002 - DHS 137AB
September 10, 2002 - DHS 137CD
November 12, 2002 - DHS 137CD

The meeting adjourned at approximately 4:00 PM by Dr. Asai.

These minutes are respectfully submitted by Kathy L. Ketchum, OSU College of Pharmacy.